BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice

Generated: December 16, 2017

DrugPatentWatch Database Preview

PLIAGLIS Drug Profile

« Back to Dashboard

Which patents cover Pliaglis, and what generic alternatives are available?

Pliaglis is a drug marketed by Taro Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in eleven countries.

The generic ingredient in PLIAGLIS is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.
Drug patent expirations by year for PLIAGLIS

Pharmacology for PLIAGLIS

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro PharmsPLIAGLISlidocaine; tetracaineCREAM;TOPICAL021717-001Jun 29, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PLIAGLIS

Country Document Number Estimated Expiration
Denmark1244401► Subscribe
European Patent Office1244401► Subscribe
Germany60032021► Subscribe
Japan2003510259► Subscribe
Spain2276697► Subscribe
Australia7719800► Subscribe
World Intellectual Property Organization (WIPO)0122907► Subscribe
Portugal1244401► Subscribe
Canada2386017► Subscribe
Japan2007126462► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Fish and Richardson
Daiichi Sankyo
Harvard Business School
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: